Research programme: age-related macular degeneration therapeutics - Perceive Biotherapeutics
Latest Information Update: 07 Jun 2022
At a glance
- Originator Perceive Biotherapeutics
- Class Eye disorder therapies
- Mechanism of Action High-temperature requirement A serine peptidase 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Age-related macular degeneration
Most Recent Events
- 18 May 2022 Early research in Age-related macular degeneration in USA (unspecified route) (Perceive Biotherapeutics pipeline, May 2022)